Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 05, 2015 5:10 AM ET

Life Sciences Tools and Services

Company Overview of Avelas BioSciences, Inc.

Company Overview

Avelas BioSciences, Inc. develops molecularly-targeted in vivo imaging technologies. It offers Avelas Cancer Illuminator, a fluorescent peptide that uses elevated protease activity of invading and metastasizing cancer to fluorescently label cancerous tissue with high sensitivity and specificity; and creates an illuminated cancer map for the surgeon during the operation when used with a fluorescence imaging system. The company also provides Avelas Nerve Illuminator, a fluorescent peptide that selectively illuminates peripheral nerves. Avelas BioSciences, Inc. was incorporated in 2008 and is based in La Jolla, California.

11099 North Torrey Pines Road

Suite 290

La Jolla, CA 92037

United States

Founded in 2008

Key Executives for Avelas BioSciences, Inc.

Chief Executive Officer, President and Director
Age: 39
Co-Founder and Research Collaborator
Vice President of Clinical Affairs
Clinical Advisor
Age: 69
Compensation as of Fiscal Year 2015.

Avelas BioSciences, Inc. Key Developments

Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients

Avelas Biosciences announced that it has initiated a Phase 1b study of its lead fluorescent cancer illuminator, AVB-620, in women with primary, non-recurrent breast cancer undergoing surgery. The open label, dose escalation study will enroll up to 39 women with stage I-III breast cancer undergoing lumpectomy or mastectomy and lymph node assessment. The study will evaluate AVB-620 safety and tolerability, pharmacokinetics, and determine the dose needed to generate fluorescence signals in tumor and lymph node tissues to enable recordings and image analysis. Additionally, the study will evaluate the effect of timing of AVB-620 administration, relative to surgery, on fluorescence characteristics.

Avelas BioSciences, Inc. Appoints Steven Chen as Vice President of Clinical Affairs

Avelas BioSciences, Inc. has appointed Steven Chen, M.D., as vice president of clinical affairs. Prior to joining Avelas Biosciences, Dr. Chen was an associate professor of surgery and the associate program director of the surgical oncology training program at City of Hope National Medical Center. Before that he served as the chief of breast surgery at UC Davis Medical Center. Dr. Chen maintains a practice in San Diego as director of surgical oncology at OasisMD. Dr. Chen serves as a director on the board of the American Society of Breast Surgeons and the Frederick A. Coller Surgical Society. He also serves on the training committee of the Society of Surgical Oncology which accredits breast surgical oncology training programs, as well as serving on a number of committees for other national professional societies including the American Medical Association and the American College of Surgeons, as well being an active member of the American Society of Clinical Oncology and the Society of University Surgeons.

Avelas BioSciences, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 08:30 AM

Avelas BioSciences, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 08:30 AM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
SiMPore Inc. United States
Cleveland Clinic Innovations United States
Sanford-Burnham Medical Research Institute United States
Certerra Inc. United States
Integrated Clinical Trial Services, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Avelas BioSciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at